**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 83067

**Manuscript Type:** REVIEW

**Distal pancreatectomy with or without radical approach, vascular resections and splenectomy: Easier does not always mean easy**

Bencini L *et al*. DP: Easier does not always mean easy

Lapo Bencini, Alessio Minuzzo

**Lapo Bencini, Alessio Minuzzo,** Oncology and Robotic Surgery, Careggi Main Regional and University Hospital, Florence 50131, Italy

**Author contributions:** Bencini L and Minuzzo A contributed to literature search and writing.

**Corresponding author: Lapo Bencini, MD, PhD, Consultant Physician-Scientist,** Oncology and Robotic Surgery, Careggi Main Regional and University Hospital, 3 Largo Brambilla, Florence 50131, Italy. bencinil@aou-careggi.toscana.it

**Received:** January 5, 2023

**Revised:** January 24, 2023

**Accepted:** April 17, 2023

**Published online:**

**Abstract**

Because distal pancreatectomy (DP) has no reconstructive steps and less frequent vascular involvement, it is thought to be the easier counterpart of pancreaticoduodenectomy. This procedure has a high surgical risk and the overall incidences of perioperative morbidity (mainly pancreatic fistula), and mortality are still high, in addition to the challenges that accompany delayed access to adjuvant therapies (if any) and prolonged impairment of daily activities. Moreover, surgery to remove malignancy of the body or tail of the pancreas is associated with poor long-term oncological outcomes. From this perspective, new surgical approaches, and aggressive techniques, such as radical antegrade modular pancreato-splenectomy and DP with celiac axis resection, could lead to improved survival in those affected by more locally advanced tumors. Conversely, minimally invasive approaches such as laparoscopic and robotic surgeries and the avoidance of routine concomitant splenectomy have been developed to reduce the burden of surgical stress. The purpose of ongoing surgical research has been to achieve significant reductions in perioperative complications, length of hospital stays and the time between surgery and the beginning of adjuvant chemotherapy. Because a dedicated multidisciplinary team is crucial to pancreatic surgery, hospital and surgeon volumes have been confirmed to be associated with better outcomes in patients affected by benign, borderline, and malignant diseases of the pancreas. The purpose of this review is to examine the state of the art in distal pancreatectomies, with a special focus on minimally invasive approaches and oncological-directed techniques. The widespread reproducibility, cost-effectiveness and long-term results of each oncological procedure are also taken into deep consideration.

**Key Words:** Distal pancreatectomy; Minimally invasive; Splenectomy; Laparoscopic

Bencini L, Minuzzo A. Distal pancreatectomy with or without radical approach, vascular resections and splenectomy: Easier does not always mean easy. *World J Gastrointest Surg* 2023; In press

**Core Tip:** Laparoscopic or robotic distal pancreatectomy is a good option to cure diseases arising from the pancreatic body/tail. The minimally-invasive approach allows to achieve concomitant splenectomy and arterial resections. However, current Literature is still lacking, and the surgical decision is based mainly on the presence of advanced laparoscopic and da Vinci equipment, controlled by skillful experts. A rigorous attention to the general and oncologic principles should be the maintained.

**INTRODUCTION**

Mesenteric vein, including the body and tail of the pancreas. Indications for distal pancreatectomy (DP) include a wide spectrum of diseases, ranging from benign to highly aggressive neoplasms. In the first group, most cases consist of chronic pancreatitis and benign cysts, while pancreatic adenocarcinoma is the most frequent pathology in the second[1]. In selected cases, DP also often requires concomitant splenectomy as a routine step of the same operation.

For pancreatic cancer, long-term survival after DP remains unsatisfactory, with a median survival time of 17-28 mo and a 5-year overall survival of approximately 20%-30%[2,3]. Despite the highly aggressive nature of the disease and early regional lymph node metastasis, adenocarcinomas of the body and tail of the pancreas have attracted significantly less clinical attention than proximal tumors[4].

Traditionally, DP is considered less challenging than pancreaticoduodenectomy, as proven by the reported lower perioperative morbidity and mortality of patients[5,6] due to the lack of reconstructive steps. Moreover, the most important postoperative complication, pancreatic fistula, is rarely life-threatening (1% mortality)[7,8]. A logical consequence of these issues led to investigating the result of minimally invasive DP (MIDP), which has been widely accepted in the worldwide surgical community[9]. Interestingly, after the first procedure reported by Cuschieri *et al*[10], MIDP has now become the procedure of choice in tertiary referral centers for both benign and malignant lesions of the body and tail of the pancreas[9,11].

Although surgical resection of the body/tail of the pancreas, achieved by an open or minimally invasive approach, is considered a less demanding operation, few evidence-based studies are available, and many issues remain unresolved. The main problems are represented by the development of postoperative pancreatic fistula (POPF) and management of the spleen (splenectomy *vs* preservation)[8,12,13].

The principal aim of this review was to investigate the ongoing surgical approaches to DP, with a special focus on minimally invasive techniques, spleen preservation and extended resections with vascular reconstruction. Endoscopic, percutaneous maneuvers and other nonsurgical maneuvers did not represent the purposes of this article and are not explained.

A web-based search of MEDLINE (accessed through PubMed and Ovid) and Cochrane databases was performed until October 2022. Many cross-matched manual references were also included. Randomized controlled clinical trials (RCTs) or meta-analyses were considered a priority. Data arising from more recent, English-written, multicentric, international studies and those with long-term follow-up and oncologic results were also considered of major interest and included in the study.

The review examines the state of the art in distal pancreatectomies, with a special focus on minimally invasive approaches and oncological-directed techniques.

**Current techniques of DP**

The operation could be defined as resection of the body-tail of the pancreas (with or without concomitant splenectomy). Globally, it includes more than 20% of all pancreatic resections[14]. The first DP was reported by Lillemoe *et al*[1], although Finney[15] and Mayo[16] collected the first case series with the description of their techniques in 1900. The surgical steps have remained unchanged for decades, and most of them are still in use.

A subcostal left transverse incision is the preferred approach, but upper midline incisions are also employed. After careful exploration, the surgeon begins by accessing the retrocavity by sectioning the greater omentum, cutting some short gastric vessels to increase the surgical view and expose the anterior surface of the pancreas. The celiac axis is then identified and dissected, and the splenic artery is transected. The pancreatic neck is gently detached from the portomesenteric confluence using a finger or blunt forceps.

The next step includes complete distal pancreatic detachment, securing each vessel originating from the splenic vein or maintaining some short gastric vessel, in the case of spleen preservation, while splenic mobilization could be achieved from left parietal ligaments in the case of concomitant splenectomy. The splenic vein should be transected distal from the inferior mesenteric vein confluence. The pancreatic neck is then transected with a selective ductal closure, and the specimen is removed. Some upgrades include vessel and/or pancreatic transection with a linear stapler, the use of a harmonic scalpel, and the employment of surgical clips[17,18].

Conventionally, DP and splenectomy have been performed to treat pancreatic cancer of the body and tail in a left-to-right retrograde fashion, in which mobilization of the spleen and pancreas is followed by vascular control and division of the pancreas[19].

After its first introduction in clinical practice, DP has substantially remained unmodified for 100 years[20,21]. In recent decades, some steps forward have been made to overcome some limits of DP and to obtain better oncological results. The most influential advances are presented below.

**Radical antegrade modular pancreato-splenectomy**

Recently, the routes of lymphatic drainage have been investigated deeply to minimize the risk factors for margin positivity and to enhance survival after DP. The acronym Radical antegrade modular pancreatosplenectomy (RAMPS) was introduced by Strasberg *et al*[20] to address some of these important issues. His technique had the goal of achieving systematic and radical surgical dissection during DP, leading to maximum rates of negative resection margins and complete regional lymph node dissection[19].

From a technical perspective, RAMPS is a “no-touch” isolation approach to control major blood vessels, such as the splenic, renal, and adrenal vessels, by early separation of the pancreatic neck from the pancreas to the spleen[22]. The major anatomic landmarks include the left-sided portal vein, the aorta, the celiac axis, the mesenteric artery, the left-sided borders and the left kidney vein and the diaphragm. The posterior margin varies according to the location and extension of the pancreatic tumor, introducing some different subclassifications of the proper “RAMPS”[23]. In detail, anterior RAMPS includes the dissection of Gerota’s fascia, the prerenal fat on the surface of the adrenal gland and the upper half of the kidney, while so-called posterior RAMPS involves the asportation of the left adrenal gland and the retroperitoneal fat tissue, with the muscle layer of the posterior abdominal wall limiting the surgical field[24].

The first published experiences reported a negative resection margin rate of up to 90%[20], although the influence of asymptomatic recurrence-free survival on overall survival remains controversial[25,26]. The systematic adoption of the RAMPS procedure has been increasing, particularly in Japan and Korea[4]. The number of patients eligible for RAMPS is small, and only recently have some prospective randomized trials of RAMPS *vs* the standard procedure been started[4,27,28]. These studies are still enrolling patients, and no definitive results are available yet. Consequently, the evidence is largely based on prospective, not randomized, studies.

Interestingly, compared to standard retrograde pancreato-splenectomy (SRPS), RAMPS has been demonstrated to reduce intraoperative bleeding[29,30] and increase R0 resection rates[4,29,30], the number of lymph nodes harvested[4,29,30] and the local recurrence rate (23.6% *vs* 49.6%; *P* = 0.019)[31], but no statistically significant difference has been found in terms of overall survival and disease-free survival[4,32]. Nevertheless, in the most recent systematic literature reviews and meta-analyses, the evidence tended to favor RAMPS in terms of safety and effectiveness (including both outcomes and overall survival)[29,33-35] with respect to SRPS, while another recent meta-analytic study suggested that RAMPS may have little effect on disease-free survival and overall survival[19].

**DP with celiac axis resection**

Locally advanced disease is present in up to 40%[36,37] of patients affected by pancreatic cancer, with a median survival reported between 6 mo to 24 mo, and the longer survival time was obtained after a somewhat systematic approach[38]. However, the surgeon may also help to obtain a more radical procedure, achieving negative margins at the price of higher complication rates. A clear benefit of more aggressive surgery has not yet been proven, and the best management is driven by the application of standardized, recognized, international guidelines that propose a chemotherapy or radio-chemotherapy approach for locally advanced cancers[39,40]. More frequently, patients undergo chemotherapy plus radiotherapy to obtain regression, with reported conversion rates (unresectable to resectable) of 33%-50% and R0 resection rates comparable to standard resections[41-44].

Based on these assumptions, demolitive surgeries, such as DP with celiac axis resection (DP-CAR), have become a therapeutic option in recent decades[45]. Nimura *et al*[46] introduced a formal DP-CAR as a modified gastric-sparing approach of the Appleby procedure[47]. It consists of concomitant DP and celiac axis resection, with the perfusion of the liver and stomach guaranteed by retrograde flow *via* the superior mesenteric artery, pancreatoduodenal arcades, and the gastroduodenal artery[48].

If venous infiltration is no longer an absolute contraindication to surgery, arterial infiltration is considered an unresectability criterion, both for technical challenges and for poor prognosis[49]. The so-called “artery-first” approach is useful as an initial surgical step to clarify arterial infiltration along the superior mesenteric artery[49]. Nevertheless, some selected patients could benefit from arterial resection if R0 margins could be obtained, with a median overall survival comparable to that of patients with localized pancreatic cancer[45,47,48,50-53]. Unfortunately, such radical surgery has high rates of morbidity (50%-80%) and mortality (3.5%-17.0%), mostly related to the liver[54] and gastric ischemia[55,56].

A systematic review by Klompmaker *et al*[48] collected the results of 19 retrospective studies published between 1975 and 2014, including a total of 240 patients. Radical resection was obtained in 75% of patients, with 27% of patients who experienced complications, with a median overall survival of 14.4[9-48] mo. Although these results were highly flawed because the percentages of neoadjuvant chemotherapy administered differed, the sample size was small, and the enrollment period was long, the conclusion is that a subgroup of patients could benefit from by this approach[47].

Interestingly, the introduction of the FOLFIRINOX chemotherapeutic schedule (folic acid, fluorouracil, irinotecan, oxaliplatin) has enhanced the neoadjuvant approach with a more aggressive approach[57,58], leading to a higher rate of resection, clear margins and significantly better survival[59]. The assumptions imply that some older surgical experiences, including aggressive vascular resections (such as DP-CAR), could have obtained suboptimal results[47].

Klompmaker *et al*[48] reported the results of an international multicenter (20 high-volume pancreatic centers) study, including a total of 68 patients with exocrine pancreatic cancer treated from 2000 to 2016. Half of them received neoadjuvant radiochemotherapy, with more than half resulting in clear margins. Additional results from this study included the following: A 25% rate of POPF, 17 d of hospital stay, and a 90-d mortality of 16%. The median overall survival was 18 mo. The authors concluded that DP-CAR offers a survival benefit in selected patients with otherwise unresectable pancreatic cancer treated by highly skilled surgical teams working at high-volume centers[47]. The best results were achieved by combining DP-CAR with chemotherapy.

Interestingly, some pioneering experiences introduced the application of the robotic platform to overcome some of the technical limitations of laparoscopic vascular resections during pancreatic surgery (Robotic DP-CAR)[47].

One of the largest reviews comparing DP-CAR and traditional DP was published by Nigri *et al*[45]. A total of 24 articles, including 1077 patients who were divided into two groups, showed a higher percentage of T4 tumors in the DP-CAR group. Perioperative outcomes were similar in terms of POPF, complications and mortality. Patients treated with DP-CAR were more likely to have positive resection margins but less likely to receive adjuvant treatments. The overall survival at one year was similar in the two groups[45]. The authors concluded that celiac axis involvement should no longer be considered a strict contraindication to surgery in patients with locally advanced pancreatic adenocarcinoma. However, a direct comparison of DP-CAR and palliative approaches should be more informative, together with a somewhat randomized design or propensity score matching. Liu *et al*[60] reported the results of a very accurate systematic review, including 11 high-quality studies and 1072 patients, concluding that DP-CAR has worse efficacy and prognosis and is more dangerous than standard DP, but it can improve survival and quality of life than palliative treatment.

Future studies should also investigate the extent of surgical volumes and the enhanced median survival in comparison to upfront resectable pancreatic cancer.

**Laparoscopic DP**

The first laparoscopic DP (LDP) was performed by Gagner *et al*[61] in the mid-nineties. Since then, laparoscopy has been widely demonstrated to reduce pain, decrease blood loss, shorten hospital stay, enhance the postoperative course, provide better cosmesis and reduce costs in many abdominal procedures[62-64]. Laparoscopic techniques have also been progressively applied in DP at the price of increased cost[64,65] and with less enthusiasm because of the position and anatomical relations with major vessels[66] when compared to open surgery. Currently, LDP has been progressively becoming the preferred approach in most centers[11].

The indications for LDP are the same as those for open DP[67-69], including benign, borderline, or malignant tumors, pancreatic injury and chronic or acute pancreatitis with pseudocysts located in the pancreatic body and tail. The invasion of the surrounding organs, vascular involvement, the presence of distant spread in cancer, or acute pancreatitis are current contraindications to a robotic approach in most centers. The minimally invasive approach should be considered more challenging in a morbidly obese patient, although skilled surgeons have reported opposite conclusions[70].

The main steps of the surgical technique are similar to those of open surgery, but no formal clear standardization of the technique has been published[71,72]. The patients are usually approached in the supine positions and tilted on the left side, and a minimum of 4 trocars are employed. Intraoperative ultrasound is recommended to identify the location of the lesion. After gentle pancreatic mobilization, the splenic vessels are identified and secured by a stapler, clips, or ligation. The pancreas is then transected using a stapler or energy device (in this case, selective duct closure is mandatory)[71].

Unfortunately, most evidence is derived from retrospective experiences, and few randomized studies have compared the minimally invasive technique with the open technique, demonstrating the superiority of MIDP in terms of reduced delayed gastric emptying, quality of life, functional recovery, reduced hospital stay, and costs[73,74]. A Cochrane review published in 2016 collected data from 12 non-RCT retrospective studies, including 1576 participants (394 LDP). No clear evidence has been reported between the two approaches in terms of short- to long-term morality and severe complications[11]. Similar conclusions were driven by the Application of the International Study Group on Pancreatic Fistula (2017) criteria, with LDP having surgical outcomes comparable with those of open DP (ODP). However, LDP resulted in lower blood loss, fewer complications, and shorter hospital stay[75].

Interestingly, LDP is underused in clinical practice[76], while ODP is still considered the standard procedure by most surgeons, including the publication of widely recognized benchmarks[77]. Despite the scarce evidence available, the application rate of LDP varied over time and differed between countries. Data extracted from nationwide database analysis reported the application of LDP in 26% of cases between 1998-2009 in the United States[78], and this rate did not exceed 10% from 2005-2013 in the Netherlands[79]. Moreover, a more recent publication from the Norwegian Patient Register reported a laparoscopic approach in 59% of DP procedures between 2012 and 2016[80].

A possible explanation of these risks could be related to the concentration of casistic in few specialized centers, which offer the maximum expertise in pancreatic pathology and highly expensive updated instrumentation. Specific participation in the training course could improve both the use and outcomes of LDP, while the initial introduction of the technique implies careful patient selection[81]. The learning curve to gain sufficient skills is reported to range between 11 and 40 procedures[81-84], and the lack of reconstructive time contributed to feeling that LDP was much more feasible than laparoscopic duodenopancreatectomy[65]. Interestingly, some authors reported similar operative times with respect to open procedures, considering it a surrogate parameter of proficiency[85,86].

Nevertheless, another possible limitation to the widespread application of LDP is the cost-effectiveness, although the balance remains difficult to evaluate due to the variability of health systems between countries and the different costs of disposable surgical devices[86]. The supposed gain in terms of the reduced hospitalization, incidence of complications, and reduction of days off-work are often misinterpreted if not available in many publications.

In 2020, an international panel of expert surgeons published guidelines for the application of minimally invasive techniques to pancreatic surgery in an attempt to overcome the uncertainties about this issue in terms of benefits and applicability and to standardize most of the indications[9,73].

The risk of POPF is the major impacting complication after open and laparoscopic DP and is highly related to prolonged intra-abdominal drainage, hemorrhage, readmissions, sepsis and certainly mortality[87,88]. Older studies reported a higher rate (39%) of POPF after minimally invasive DP compared to open DP[89], but others failed to find significant differences after careful statistical patient stratification and homogenization[90]. Moreover, in 2021, a new POPF risk score (ua-FRS) was validated for minimally invasive pancreatic surgery[91], with a reported global incidence rate of 21%. A careful surgical technique, independent of the approach (open or minimally invasive), is the best option to minimize the risk of POPF[91]. Many different approaches (some comparative) to pancreatic transection have been published, including scalpel, electrocautery, ultrasonic/harmonic, and laparoscopic staplers[92-97], but no evidence is available to support one method over another, and most evidence is derived from ODP studies. The use of fibrin sealants and similar products has little effect on POPF in people undergoing DP[96,97].

Many researchers hypothesize some advantages of MIS in decreasing the proinflammatory and immunologic response to surgical trauma[98,99] that is associated with a superior oncologic result, while a robust meta-analysis demonstrated that LDP might be safer with regard to the oncological outcomes of pancreatic ductal adenocarcinoma patients[100]. A study by Shin *et al*[101] specifically compared LDP and ODP in 150 cancerous patients, with oncologic adequacy considered the primary endpoint. The authors reported a 5-year survival rate, the length of surgery, the number of harvested lymph nodes, the resection margin status, and the incidence of POPF to be similar between the two groups.

Spleen preservation is considered to be mandatory for patients operated on for IPMN or less aggressive neuroendocrine tumors located in the pancreatic body and tail, leading to a reduction in both blood loss and postoperative complications[102-108]. Warshaw[109] described a technique in which splenic vessels are ligated with the preservation of the short gastric and left gastroepiploic vessels, while Kimura spared the splenic vessels by careful detachment of pancreatic vessels from the major trunks[110]. Although this concept has recently been discussed, the two available spleen-preservation techniques[111,112] are feasible by laparoscopy in the hands of experienced surgeons[111]. Most published papers reported similar rates of spleen preservation[103,105,106].

**Robotic DP**

The recent, widespread introduction of the da Vinci® Surgical Systems (Intuitive Surgical, Inc., Sunnyvale, CA, United States) robot has led many surgeons to address pancreatic disease with this technology[113]. If minimally invasive pancreaticoduodenectomy (laparoscopic, hybrid, or robotic) is far from routinely adopted in the community, robotic-assisted distal pancreatic resection (RDP) should potentially resolve many of the major issues of pure laparoscopy, including the preservation of the spleen[114]. For example, few retrospective series have reported the percentages of the spleen left in situ (when indicated) in up to 90% of cases[115,116], while neither the traditional open nor laparoscopic approach has been reported to reach 90%[117]. In addition, robotic articulated stable instrumentation could help the surgeon improve tissue dissection and lymphadenectomy when treating pancreatic cancer[118-120]. Nevertheless, definitive data on the robotic approach are still needed.

A meta-analysis by Zhang *et al*[121], which included seven trials, examined 137 robotic and 203 open pancreatectomies. Many of the analyzed parameters, such as morbidity, blood loss and length of hospital stay, favored robotic procedures, but none of the differences reached statistical significance. The incidence of POPF was similar.

Another more recent meta-analysis by Feng *et al*[122] reported better results of RDP compared to LDP in terms of operative time, tumor size, and lymph node dissection, with a higher R0 resection rate (*P* < 0.0001)[122]. Other meta-analyses comparing RDP and LDP reported the former as safe and feasible, with a low rate of conversion to open surgery, blood loss, a shorter length of stay and an increased rate of spleen preservation[117,123]. However, demographic discrepancies, underpowered RDP samples and differences in oncological burden do not permit certain conclusions regarding the oncological safety of RDP and LDP for pancreatic adenocarcinoma[123]. The oncological safety of robotic DP compared to LDP has been demonstrated[2] in a national database and is currently being evaluated in a multicenter European randomized trial (DIPLOMA trial)[124].

In conclusion, robotic DP is a safe and feasible procedure with perioperative and oncological outcomes comparable to those of LDP and open traditional surgery. Many technical advantages seem to permit the surgeon to overcome many of the drawbacks of pure laparoscopy, including a steep learning curve, complex dissection and ergonomic issues, maintaining the same advantages of a minimally invasive procedure (reduced blood loss, shorter hospitalization and improved cosmetic results)[113]. Costs and availability remain the main limitations of the robotic approach[125] (Table 1).

**CONCLUSION**

Surgical resection has the best chance to cure pancreatic disease, including malignancy, precancerous lesions, and inflammatory involvement. Nevertheless, pancreatic surgery has high morbidity and mortality rates and is especially challenging for surgeons operating on elderly surgical patients. Therefore, the purpose of ongoing research and surgical efforts is to reduce the impact of surgical trauma through minimally invasive approaches, spleen preservation when indicated, and maintaining and improving the accuracy of oncologic dissection (*i.e.*, clear margins and proper lymphadenectomy). All the issues mentioned above can be addressed by laparoscopic and robotic surgeries, which have been well established for distal pancreatic resections. However, such procedures require excellent surgical skill, training experience with proctors, and case-load concentration in high-volume hospitals with the best resources. In conclusion, if DP with or without a radical approach, vascular resection or splenectomy is thought to be easier than cephalic resection, it should not be considered easy in every case.

**REFERENCES**

1 **Lillemoe KD**, Kaushal S, Cameron JL, Sohn TA, Pitt HA, Yeo CJ. Distal pancreatectomy: indications and outcomes in 235 patients. *Ann Surg* 1999; **229**: 693-8; discussion 698-700 [PMID: 10235528 DOI: 10.1097/00000658-199905000-00012]

2 **Raoof M**, Nota CLMA, Melstrom LG, Warner SG, Woo Y, Singh G, Fong Y. Oncologic outcomes after robot-assisted versus laparoscopic distal pancreatectomy: Analysis of the National Cancer Database. *J Surg Oncol* 2018; **118**: 651-656 [PMID: 30114321 DOI: 10.1002/jso.25170]

3 **de Rooij T**, Tol JA, van Eijck CH, Boerma D, Bonsing BA, Bosscha K, van Dam RM, Dijkgraaf MG, Gerhards MF, van Goor H, van der Harst E, de Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Patijn GA, van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. *Ann Surg Oncol* 2016; **23**: 585-591 [PMID: 26508153 DOI: 10.1245/s10434-015-4930-4]

4 **Cao F**, Li J, Li A, Li F. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: A systemic review and meta-analysis. *BMC Surg* 2017; **17**: 67 [PMID: 28583142 DOI: 10.1186/s12893-017-0259-1]

5 **Durin T**, Marchese U, Sauvanet A, Dokmak S, Cherkaoui Z, Fuks D, Laurent C, André M, Ayav A, Magallon C, Turrini O, Sulpice L, Robin F, Bachellier P, Addeo P, Souche FR, Bardol T, Perinel J, Adham M, Tzedakis S, Birnbaum DJ, Facy O, Gagniere J, Gaujoux S, Tribillon E, Roussel E, Schwarz L, Barbier L, Doussot A, Regenet N, Iannelli A, Regimbeau JM, Piessen G, Lenne X, Truant S, El Amrani M. Defining Benchmark Outcomes for Distal Pancreatectomy: Results of a French Multicentric Study. *Ann Surg* 2022 [PMID: 35762617 DOI: 10.1097/SLA.0000000000005539]

6 **Müller PC**, Breuer E, Nickel F, Zani S Jr, Kauffmann E, De Franco L, Tschuor C, Suno Krohn P, Burgdorf SK, Jonas JP, Oberkofler CE, Petrowsky H, Saint-Marc O, Seelen L, Molenaar IQ, Wellner U, Keck T, Coratti A, van Dam C, de Wilde R, Koerkamp BG, Valle V, Giulianotti P, Ghabi E, Moskal D, Lavu H, Vrochides D, Martinie J, Yeo C, Sánchez-Velázquez P, Ielpo B, Ajay PS, Shah MM, Kooby DA, Gao S, Hao J, He J, Boggi U, Hackert T, Allen P, Borel-Rinkes IHM, Clavien PA. Robotic Distal Pancreatectomy, a Novel Standard of Care? Benchmark Values for Surgical Outcomes from 16 International Expert Centers. *Ann Surg* 2022 [PMID: 35861061 DOI: 10.1097/SLA.0000000000005601]

7 **Pedrazzoli S**. Pancreatoduodenectomy (PD) and postoperative pancreatic fistula (POPF): A systematic review and analysis of the POPF-related mortality rate in 60,739 patients retrieved from the English literature published between 1990 and 2015. *Medicine (Baltimore)* 2017; **96**: e6858 [PMID: 28489778 DOI: 10.1097/MD.0000000000006858]

8 **Al Abbas AI**, Zeh Iii HJ, Polanco PM. State of the art robotic distal pancreatectomy: a review of the literature. *Updates Surg* 2021; **73**: 881-891 [PMID: 34050901 DOI: 10.1007/s13304-021-01070-y]

9 **Asbun HJ**, Moekotte AL, Vissers FL, Kunzler F, Cipriani F, Alseidi A, D'Angelica MI, Balduzzi A, Bassi C, Björnsson B, Boggi U, Callery MP, Del Chiaro M, Coimbra FJ, Conrad C, Cook A, Coppola A, Dervenis C, Dokmak S, Edil BH, Edwin B, Giulianotti PC, Han HS, Hansen PD, van der Heijde N, van Hilst J, Hester CA, Hogg ME, Jarufe N, Jeyarajah DR, Keck T, Kim SC, Khatkov IE, Kokudo N, Kooby DA, Korrel M, de Leon FJ, Lluis N, Lof S, Machado MA, Demartines N, Martinie JB, Merchant NB, Molenaar IQ, Moravek C, Mou YP, Nakamura M, Nealon WH, Palanivelu C, Pessaux P, Pitt HA, Polanco PM, Primrose JN, Rawashdeh A, Sanford DE, Senthilnathan P, Shrikhande SV, Stauffer JA, Takaori K, Talamonti MS, Tang CN, Vollmer CM, Wakabayashi G, Walsh RM, Wang SE, Zinner MJ, Wolfgang CL, Zureikat AH, Zwart MJ, Conlon KC, Kendrick ML, Zeh HJ, Hilal MA, Besselink MG; International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS). The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. *Ann Surg* 2020; **271**: 1-14 [PMID: 31567509 DOI: 10.1097/SLA.0000000000003590]

10 **Cuschieri A**, Jakimowicz JJ, van Spreeuwel J. Laparoscopic distal 70% pancreatectomy and splenectomy for chronic pancreatitis. *Ann Surg* 1996; **223**: 280-285 [PMID: 8604908 DOI: 10.1097/00000658-199603000-00008]

11 **Riviere D**, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, van Laarhoven CJ. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. *Cochrane Database Syst Rev* 2016; **4**: CD011391 [PMID: 27043078 DOI: 10.1002/14651858.CD011391.pub2]

12 **Jiwani A**, Chawla T. Risk Factors of Pancreatic Fistula in Distal Pancreatectomy Patients. *Surg Res Pract* 2019; **2019**: 4940508 [PMID: 31396547 DOI: 10.1155/2019/4940508]

13 **Jiang L**, Ning D, Chen XP. Improvement in distal pancreatectomy for tumors in the body and tail of the pancreas. *World J Surg Oncol* 2021; **19**: 49 [PMID: 33588845 DOI: 10.1186/s12957-021-02159-9]

14 **Seppänen H**, Juuti A, Mustonen H, Haapamäki C, Nordling S, Carpelan-Holmström M, Sirén J, Luettges J, Haglund C, Kiviluoto T. The Results of Pancreatic Resections and Long-Term Survival for Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience. *Scand J Surg* 2017; **106**: 54-61 [PMID: 27130378 DOI: 10.1177/1457496916645963]

15 **Finney JM**. VII. Resection of the Pancreas: Report of a Case. *Ann Surg* 1910; **51**: 818-829 [PMID: 17862541 DOI: 10.1097/00000658-191006000-00007]

16 **Mayo WJ**. I. The Surgery of the Pancreas: I. Injuries to the Pancreas in the Course of Operations on the Stomach. II. Injuries to the Pancreas in the Course of Operations on the Spleen. III. Resection of Half the Pancreas for Tumor. *Ann Surg* 1913; **58**: 145-150 [PMID: 17863043 DOI: 10.1097/00000658-191308000-00001]

17 **Diener MK**, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G, Tomazic A, Bruns CJ, Busch OR, Farkas S, Belyaev O, Neoptolemos JP, Halloran C, Keck T, Niedergethmann M, Gellert K, Witzigmann H, Kollmar O, Langer P, Steger U, Neudecker J, Berrevoet F, Ganzera S, Heiss MM, Luntz SP, Bruckner T, Kieser M, Büchler MW. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. *Lancet* 2011; **377**: 1514-1522 [PMID: 21529927 DOI: 10.1016/S0140-6736(11)60237-7]

18 **Sugo H**, Mikami Y, Matsumoto F, Tsumura H, Watanabe Y, Futagawa S. Comparison of ultrasonically activated scalpel versus conventional division for the pancreas in distal pancreatectomy. *J Hepatobiliary Pancreat Surg* 2001; **8**: 349-352 [PMID: 11521180 DOI: 10.1007/s005340170007]

19 **Watanabe G**, Ito H, Sato T, Ono Y, Mise Y, Inoue Y, Takahashi Y, Saiura A. Left kidney mobilization technique during radical antegrade modular pancreatosplenectomy (RAMPS). *Langenbecks Arch Surg* 2019; **404**: 247-252 [PMID: 30810806 DOI: 10.1007/s00423-019-01767-0]

20 **Strasberg SM**, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. *Surgery* 2003; **133**: 521-527 [PMID: 12773980 DOI: 10.1067/msy.2003.146]

21 **Trottman P**, Swett K, Shen P, Sirintrapun J. Comparison of standard distal pancreatectomy and splenectomy with radical antegrade modular pancreatosplenectomy. *Am Surg* 2014; **80**: 295-300 [PMID: 24666872]

22 **Kuroki T**, Eguchi S. No-touch isolation techniques for pancreatic cancer. *Surg Today* 2017; **47**: 8-13 [PMID: 26931548 DOI: 10.1007/s00595-016-1317-5]

23 **Kitagawa H**, Tajima H, Nakagawara H, Makino I, Miyashita T, Terakawa H, Nakanuma S, Hayashi H, Takamura H, Ohta T. A modification of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the left pancreas: significance of en bloc resection including the anterior renal fascia. *World J Surg* 2014; **38**: 2448-2454 [PMID: 24752361 DOI: 10.1007/s00268-014-2572-5]

24 **Chun YS**. Role of Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Pancreatic Cancer. *Ann Surg Oncol* 2018; **25**: 46-50 [PMID: 27848048 DOI: 10.1245/s10434-016-5675-4]

25 **Park HJ**, You DD, Choi DW, Heo JS, Choi SH. Role of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. *World J Surg* 2014; **38**: 186-193 [PMID: 24166024 DOI: 10.1007/s00268-013-2254-8]

26 **Nießen A**, Hackert T. State-of-the-art surgery for pancreatic cancer. *Langenbecks Arch Surg* 2022; **407**: 443-450 [PMID: 34751822 DOI: 10.1007/s00423-021-02362-y]

27 **Zhang G**, Kang Y, Zhang H, Wang F, Liu R. Robotic radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS): study protocol for a randomized controlled trial. *Trials* 2020; **21**: 306 [PMID: 32245518 DOI: 10.1186/s13063-020-04250-0]

28 **U.S. National Library of Medicine**. Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (REMIND-01). 2018. [cited 1 April 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT03679169

29 **Zhou Q**, Fengwei-Gao, Gong J, Xie Q, Liu Y, Wang Q, Lei Z. Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review. *BMC Surg* 2019; **19**: 12 [PMID: 30691444 DOI: 10.1186/s12893-019-0476-x]

30 **Abe T**, Ohuchida K, Miyasaka Y, Ohtsuka T, Oda Y, Nakamura M. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sided Pancreatic Cancer. *World J Surg* 2016; **40**: 2267-2275 [PMID: 27138881 DOI: 10.1007/s00268-016-3526-x]

31 **Kiritani S**, Kaneko J, Arita J, Ishizawa T, Akamatsu N, Hasegawa K. Radical Antegrade Modular Pancreatosplenectomy for Left-Sided Pancreatic Ductal Adenocarcinoma May Reduce the Local Recurrence Rate. *Dig Surg* 2022; **39**: 191-200 [PMID: 35533649 DOI: 10.1159/000524927]

32 **Kim HS**, Hong TH, You YK, Park JS, Yoon DS. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study. *Surg Today* 2021; **51**: 1775-1786 [PMID: 33830293 DOI: 10.1007/s00595-021-02280-y]

33 **Dragomir M**, Eftimie MA. Is Radical Antegrade Modular Pancreatosplenectomy the Solution? A Systematic Literature Review and Meta-Analysis. *Chirurgia (Bucur)* 2017; **112**: 653-663 [PMID: 29288607 DOI: 10.21614/chirurgia.112.6.653]

34 **Huo Z**, Zhai S, Wang Y, Qian H, Tang X, Shi Y, Weng Y, Zhao S, Deng X, Shen B. Comparison of Radical Antegrade Modular Pancreatosplenectomy with Standard Retrograde Pancreatosplenectomy for Left-Sided Pancreatic Cancer: A Meta-Analysis and Experience of a Single Center. *Med Sci Monit* 2019; **25**: 4590-4601 [PMID: 31221951 DOI: 10.12659/MSM.914540]

35 **Zhou Y**, Shi B, Wu L, Si X. A systematic review of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. *HPB (Oxford)* 2017; **19**: 10-15 [PMID: 27553838 DOI: 10.1016/j.hpb.2016.07.014]

36 **Walma MS**, Brada LJ, Patuleia SIS, Blomjous JG, Bollen TL, Bosscha K, Bruijnen RC, Busch OR, Creemers GJ, Daams F, van Dam R, Festen S, Jan de Groot D, Willem de Groot J, Mohammad NH, Hermans JJ, de Hingh IH, Kerver ED, van Leeuwen MS, van der Leij C, Liem MS, van Lienden KP, Los M, de Meijer VE, Meijerink MR, Mekenkamp LJ, Nederend J, Nio CY, Patijn GA, Polée MB, Pruijt JF, Renken NS, Rombouts SJ, Schouten TJ, Stommel MWJ, Verweij ME, de Vos-Geelen J, de Vries JJJ, Vulink A, Wessels FJ, Wilmink JW, van Santvoort HC, Besselink MG, Molenaar IQ; Dutch Pancreatic Cancer Group. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. *Eur J Surg Oncol* 2021; **47**: 699-707 [PMID: 33280952 DOI: 10.1016/j.ejso.2020.11.137]

37 **Ruarus A**, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. *Cancers (Basel)* 2018; **10** [PMID: 29320420 DOI: 10.3390/cancers10010016]

38 **Klompmaker S**, van Hilst J, Gerritsen SL, Adham M, Teresa Albiol Quer M, Bassi C, Berrevoet F, Boggi U, Busch OR, Cesaretti M, Dalla Valle R, Darnis B, De Pastena M, Del Chiaro M, Grützmann R, Diener MK, Dumitrascu T, Friess H, Ivanecz A, Karayiannakis A, Fusai GK, Labori KJ, Lombardo C, López-Ben S, Mabrut JY, Niesen W, Pardo F, Perinel J, Popescu I, Roeyen G, Sauvanet A, Prasad R, Sturesson C, Lesurtel M, Kleeff J, Salvia R, Besselink MG; E-AHPBA DP-CAR study group. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. *Ann Surg Oncol* 2018; **25**: 1440-1447 [PMID: 29532342 DOI: 10.1245/s10434-018-6391-z]

39 **Tempero MA**, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021; **19**: 439-457 [PMID: 33845462 DOI: 10.6004/jnccn.2021.0017]

40 **Ducreux M**, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; **26 Suppl 5**: v56-v68 [PMID: 26314780 DOI: 10.1093/annonc/mdv295]

41 **Strobel O**, Berens V, Hinz U, Hartwig W, Hackert T, Bergmann F, Debus J, Jäger D, Büchler MW, Werner J. Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. *Surgery* 2012; **152**: S33-S42 [PMID: 22770956 DOI: 10.1016/j.surg.2012.05.029]

42 **Allendorf JD**, Lauerman M, Bill A, DiGiorgi M, Goetz N, Vakiani E, Remotti H, Schrope B, Sherman W, Hall M, Fine RL, Chabot JA. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. *J Gastrointest Surg* 2008; **12**: 91-100 [PMID: 17786524 DOI: 10.1007/s11605-007-0296-7]

43 **Cheng TY**, Sheth K, White RR, Ueno T, Hung CF, Clary BM, Pappas TN, Tyler DS. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. *Ann Surg Oncol* 2006; **13**: 66-74 [PMID: 16372154 DOI: 10.1245/ASO.2006.02.003]

44 **Massucco P**, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. *Ann Surg Oncol* 2006; **13**: 1201-1208 [PMID: 16955382 DOI: 10.1245/s10434-006-9032-x]

45 **Nigri G**, Petrucciani N, Belloni E, Lucarini A, Aurello P, D'Angelo F, di Saverio S, Fancellu A, Ramacciato G. Distal Pancreatectomy with Celiac Axis Resection: Systematic Review and Meta-Analysis. *Cancers (Basel)* 2021; **13** [PMID: 33921838 DOI: 10.3390/cancers13081967]

46 **Nimura Y**, Hattory T, Miura K, Nakashima, N, Hibi M. Our experience of resection of carcinoma of the body and tail of the pancreas by Appleby’s procedure. *Operation* 1976; **15**: 885-889

47 **Klompmaker S**, Boggi U, Hackert T, Salvia R, Weiss M, Yamaue H, Zeh HJ, Besselink MG. Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. *J Gastrointest Surg* 2018; **22**: 1804-1810 [PMID: 30105677 DOI: 10.1007/s11605-018-3894-7]

48 **Klompmaker S**, de Rooij T, Korteweg JJ, van Dieren S, van Lienden KP, van Gulik TM, Busch OR, Besselink MG. Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. *Br J Surg* 2016; **103**: 941-949 [PMID: 27304847 DOI: 10.1002/bjs.10148]

49 **Hackert T**, Schneider L, Büchler MW. Current State of Vascular Resections in Pancreatic Cancer Surgery. *Gastroenterol Res Pract* 2015; **2015**: 120207 [PMID: 26609306 DOI: 10.1155/2015/120207]

50 **Ocuin LM**, Miller-Ocuin JL, Novak SM, Bartlett DL, Marsh JW, Tsung A, Lee KK, Hogg ME, Zeh HJ, Zureikat AH. Robotic and open distal pancreatectomy with celiac axis resection for locally advanced pancreatic body tumors: a single institutional assessment of perioperative outcomes and survival. *HPB (Oxford)* 2016; **18**: 835-842 [PMID: 27506992 DOI: 10.1016/j.hpb.2016.05.003]

51 **Peters NA**, Javed AA, Cameron JL, Makary MA, Hirose K, Pawlik TM, He J, Wolfgang CL, Weiss MJ. Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach? *Ann Surg Oncol* 2016; **23**: 3757-3764 [PMID: 27328946 DOI: 10.1245/s10434-016-5303-3]

52 **Sugiura T**, Okamura Y, Ito T, Yamamoto Y, Uesaka K. Surgical Indications of Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Body/Tail Cancer. *World J Surg* 2017; **41**: 258-266 [PMID: 27473130 DOI: 10.1007/s00268-016-3670-3]

53 **Nakamura T**, Hirano S, Noji T, Asano T, Okamura K, Tsuchikawa T, Murakami S, Kurashima Y, Ebihara Y, Nakanishi Y, Tanaka K, Shichinohe T. Distal Pancreatectomy with en Bloc Celiac Axis Resection (Modified Appleby Procedure) for Locally Advanced Pancreatic Body Cancer: A Single-Center Review of 80 Consecutive Patients. *Ann Surg Oncol* 2016; **23**: 969-975 [PMID: 27495282 DOI: 10.1245/s10434-016-5493-8]

54 **Ueda A**, Sakai N, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takano S, Suzuki D, Kagawa S, Mishima T, Nakadai E, Miyazaki M, Ohtsuka M. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? *World J Surg Oncol* 2019; **17**: 124 [PMID: 31315628 DOI: 10.1186/s12957-019-1667-8]

55 **Latona JA**, Lamb KM, Pucci MJ, Maley WR, Yeo CJ. Modified Appleby Procedure with Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma: A Literature Review and Report of Three Unusual Cases. *J Gastrointest Surg* 2016; **20**: 300-306 [PMID: 26525205 DOI: 10.1007/s11605-015-3001-2]

56 **Hirano S**, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, Suzuki O, Hazama K. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. *Ann Surg* 2007; **246**: 46-51 [PMID: 17592290 DOI: 10.1097/01.sla.0000258608.52615.5a]

57 **Suker M**, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. *Lancet Oncol* 2016; **17**: 801-810 [PMID: 27160474 DOI: 10.1016/S1470-2045(16)00172-8]

58 **Conroy T**, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; **364**: 1817-1825 [PMID: 21561347 DOI: 10.1056/NEJMoa1011923]

59 **Murakami Y**, Nakagawa N, Kondo N, Hashimoto Y, Okada K, Seo S, Otsuka H. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. *Pancreatology* 2021; **21**: 564-572 [PMID: 33526385 DOI: 10.1016/j.pan.2021.01.008]

60 **Liu L**, Liu TX, Huang WX, Yang Z, Wang S, Da MX, Dong Y. Distal pancreatectomy with En bloc celiac axis resection for locally advanced pancreatic body/tail cancer: A systematic review and meta-analysis. *Asian J Surg* 2022; **45**: 51-61 [PMID: 34187724 DOI: 10.1016/j.asjsur.2021.06.002]

61 **Gagner M**, Pomp A, Herrera MF. Early experience with laparoscopic resections of islet cell tumors. *Surgery* 1996; **120**: 1051-1054 [PMID: 8957494 DOI: 10.1016/S0039-6060(96)80054-7]

62 **Schwenk W**, Haase O, Neudecker J, Müller JM. Short term benefits for laparoscopic colorectal resection. *Cochrane Database Syst Rev* 2005; **2005**: CD003145 [PMID: 16034888 DOI: 10.1002/14651858.CD003145.pub2]

63 **Edwin B**, Sahakyan MA, Abu Hilal M, Besselink MG, Braga M, Fabre JM, Fernández-Cruz L, Gayet B, Kim SC, Khatkov IE; EAES Consensus Conference Study Group. Laparoscopic surgery for pancreatic neoplasms: the European association for endoscopic surgery clinical consensus conference. *Surg Endosc* 2017; **31**: 2023-2041 [PMID: 28205034 DOI: 10.1007/s00464-017-5414-3]

64 **Braga M**, Pecorelli N, Ferrari D, Balzano G, Zuliani W, Castoldi R. Results of 100 consecutive laparoscopic distal pancreatectomies: postoperative outcome, cost-benefit analysis, and quality of life assessment. *Surg Endosc* 2015; **29**: 1871-1878 [PMID: 25294551 DOI: 10.1007/s00464-014-3879-x]

65 **Fingerhut A**, Uranues S, Khatkov I, Boni L. Laparoscopic distal pancreatectomy: better than open? *Transl Gastroenterol Hepatol* 2018; **3**: 49 [PMID: 30225383 DOI: 10.21037/tgh.2018.07.04]

66 **Vijan SS**, Ahmed KA, Harmsen WS, Que FG, Reid-Lombardo KM, Nagorney DM, Donohue JH, Farnell MB, Kendrick ML. Laparoscopic vs open distal pancreatectomy: a single-institution comparative study. *Arch Surg* 2010; **145**: 616-621 [PMID: 20644122 DOI: 10.1001/archsurg.2010.120]

67 **Mehrabi A**, Hafezi M, Arvin J, Esmaeilzadeh M, Garoussi C, Emami G, Kössler-Ebs J, Müller-Stich BP, Büchler MW, Hackert T, Diener MK. A systematic review and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and malignant lesions of the pancreas: it's time to randomize. *Surgery* 2015; **157**: 45-55 [PMID: 25482464 DOI: 10.1016/j.surg.2014.06.081]

68 **Goh BK**, Tan YM, Chung YF, Cheow PC, Ong HS, Chan WH, Chow PK, Soo KC, Wong WK, Ooi LL. Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. *Arch Surg* 2008; **143**: 956-965 [PMID: 18936374 DOI: 10.1001/archsurg.143.10.956]

69 **Uranues S**, Alimoglu O, Todoric B, Toprak N, Auer T, Rondon L, Sauseng G, Pfeifer J. Laparoscopic resection of the pancreatic tail with splenic preservation. *Am J Surg* 2006; **192**: 257-261 [PMID: 16860642 DOI: 10.1016/j.amjsurg.2006.01.031]

70 **Røsok BI**, de Rooij T, van Hilst J, Diener MK, Allen PJ, Vollmer CM, Kooby DA, Shrikhande SV; Organizing Committee for the State of the Art Conference on Minimally Invasive Pancreas Resection. Minimally invasive distal pancreatectomy. *HPB (Oxford)* 2017; **19**: 205-214 [PMID: 28215903 DOI: 10.1016/j.hpb.2017.01.009]

71 **Edwin B**, Mala T, Mathisen Ø, Gladhaug I, Buanes T, Lunde OC, Søreide O, Bergan A, Fosse E. Laparoscopic resection of the pancreas: a feasibility study of the short-term outcome. *Surg Endosc* 2004; **18**: 407-411 [PMID: 14752628 DOI: 10.1007/s00464-003-9007-y]

72 **Selvaggi F**, Testa DC, Panaccio P, Rossi S, Raimondi P, Ciampaglia M, Mazzola L, Cotellese R. Minimally invasive distal pancreatectomy: mapping surgical maneuvers towards operative standardization. *Ann Ital Chir* 2022; **92**: 122-129 [PMID: 34645715]

73 **Korrel M**, Roelofs A, van Hilst J, Busch OR, Daams F, Festen S, Groot Koerkamp B, Klaase J, Luyer MD, van Oijen MG, Verdonck-de Leeuw IM, Besselink MG; LEOPARD Trial Collaborators. Long-Term Quality of Life after Minimally Invasive vs Open Distal Pancreatectomy in the LEOPARD Randomized Trial. *J Am Coll Surg* 2021; **233**: 730-739.e9 [PMID: 34530127 DOI: 10.1016/j.jamcollsurg.2021.08.687]

74 **Björnsson B**, Lindhoff Larsson A, Hjalmarsson C, Gasslander T, Sandström P. Author response to: Comment on: Comparison of the duration of hospital stay after laparoscopic or open distal pancreatectomy: randomized controlled trial. *Br J Surg* 2020; **107**: e279 [PMID: 32445396 DOI: 10.1002/bjs.11681]

75 **Chen K**, Pan Y, Huang CJ, Chen QL, Zhang RC, Zhang MZ, Wang GY, Wang XF, Mou YP, Yan JF. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy. *BMC Cancer* 2021; **21**: 382 [PMID: 33836678 DOI: 10.1186/s12885-021-08117-8]

76 **Rosales-Velderrain A**, Bowers SP, Goldberg RF, Clarke TM, Buchanan MA, Stauffer JA, Asbun HJ. National trends in resection of the distal pancreas. *World J Gastroenterol* 2012; **18**: 4342-4349 [PMID: 22969197 DOI: 10.3748/wjg.v18.i32.4342]

77 **Tseng WH**, Canter RJ, Bold RJ. Perioperative outcomes for open distal pancreatectomy: current benchmarks for comparison. *J Gastrointest Surg* 2011; **15**: 2053-2058 [PMID: 21938560 DOI: 10.1007/s11605-011-1677-5]

78 **Dudekula A**, Munigala S, Zureikat AH, Yadav D. Operative Trends for Pancreatic Diseases in the USA: Analysis of the Nationwide Inpatient Sample from 1998-2011. *J Gastrointest Surg* 2016; **20**: 803-811 [PMID: 26791389 DOI: 10.1007/s11605-015-3067-x]

79 **de Rooij T**, Jilesen AP, Boerma D, Bonsing BA, Bosscha K, van Dam RM, van Dieren S, Dijkgraaf MG, van Eijck CH, Gerhards MF, van Goor H, van der Harst E, de Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Nieveen van Dijkum EJ, Patijn GA, van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E, Vogel JA, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. A nationwide comparison of laparoscopic and open distal pancreatectomy for benign and malignant disease. *J Am Coll Surg* 2015; **220**: 263-270.e1 [PMID: 25600974 DOI: 10.1016/j.jamcollsurg.2014.11.010]

80 **Søreide K**, Olsen F, Nymo LS, Kleive D, Lassen K. A nationwide cohort study of resection rates and short-term outcomes in open and laparoscopic distal pancreatectomy. *HPB (Oxford)* 2019; **21**: 669-678 [PMID: 30391219 DOI: 10.1016/j.hpb.2018.10.006]

81 **Braga M**, Ridolfi C, Balzano G, Castoldi R, Pecorelli N, Di Carlo V. Learning curve for laparoscopic distal pancreatectomy in a high-volume hospital. *Updates Surg* 2012; **64**: 179-183 [PMID: 22763577 DOI: 10.1007/s13304-012-0163-2]

82 **Sahakyan MA**, Røsok BI, Tholfsen T, Kleive D, Waage A, Ignjatovic D, Buanes T, Labori KJ, Edwin B. Implementation and training with laparoscopic distal pancreatectomy: 23-year experience from a high-volume center. *Surg Endosc* 2022; **36**: 468-479 [PMID: 33534075 DOI: 10.1007/s00464-021-08306-3]

83 **Fung G**, Sha M, Kunduzi B, Froghi F, Rehman S, Froghi S. Learning curves in minimally invasive pancreatic surgery: a systematic review. *Langenbecks Arch Surg* 2022; **407**: 2217-2232 [PMID: 35278112 DOI: 10.1007/s00423-022-02470-3]

84 **Ricci C**, Casadei R, Buscemi S, Taffurelli G, D'Ambra M, Pacilio CA, Minni F. Laparoscopic distal pancreatectomy: what factors are related to the learning curve? *Surg Today* 2015; **45**: 50-56 [PMID: 24610347 DOI: 10.1007/s00595-014-0872-x]

85 **Finan KR**, Cannon EE, Kim EJ, Wesley MM, Arnoletti PJ, Heslin MJ, Christein JD. Laparoscopic and open distal pancreatectomy: a comparison of outcomes. *Am Surg* 2009; **75**: 671-9; discussion 679-80 [PMID: 19725289 DOI: 10.1177/000313480907500807]

86 **Gurusamy KS**, Riviere D, van Laarhoven CJH, Besselink M, Abu-Hilal M, Davidson BR, Morris S. Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer. *PLoS One* 2017; **12**: e0189631 [PMID: 29272281 DOI: 10.1371/journal.pone.0189631]

87 **Peng YP**, Zhu XL, Yin LD, Zhu Y, Wei JS, Wu JL, Miao Y. Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis. *Sci Rep* 2017; **7**: 185 [PMID: 28298641 DOI: 10.1038/s41598-017-00311-8]

88 **Bassi C**, Buchler MW, Fingerhut A, Sarr M. Predictive factors for postoperative pancreatic fistula. *Ann Surg* 2015; **261**: e99 [PMID: 24441806 DOI: 10.1097/SLA.0000000000000577]

89 **van der Heijde N**, Lof S, Busch OR, de Hingh I, de Kleine RH, Molenaar IQ, Mungroop TH, Stommel MW, Besselink MG, van Eijck C; Dutch Pancreatic Cancer Group. Incidence and impact of postoperative pancreatic fistula after minimally invasive and open distal pancreatectomy. *Surgery* 2022; **171**: 1658-1664 [PMID: 34906371 DOI: 10.1016/j.surg.2021.11.009]

90 **Kollár D**, Huszár T, Pohárnok Z, Cselovszky É, Oláh A. A Review of Techniques for Closure of the Pancreatic Remnant following Distal Pancreatectomy. *Dig Surg* 2016; **33**: 320-328 [PMID: 27215609 DOI: 10.1159/000445017]

91 **Mungroop TH**, Klompmaker S, Wellner UF, Steyerberg EW, Coratti A, D'Hondt M, de Pastena M, Dokmak S, Khatkov I, Saint-Marc O, Wittel U, Abu Hilal M, Fuks D, Poves I, Keck T, Boggi U, Besselink MG; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Updated Alternative Fistula Risk Score (ua-FRS) to Include Minimally Invasive Pancreatoduodenectomy: Pan-European Validation. *Ann Surg* 2021; **273**: 334-340 [PMID: 30829699 DOI: 10.1097/SLA.0000000000003234]

92 **Landoni L**, De Pastena M, Fontana M, Malleo G, Esposito A, Casetti L, Marchegiani G, Tuveri M, Paiella S, Pea A, Ramera M, Borin A, Giardino A, Frigerio I, Girelli R, Bassi C, Butturini G, Salvia R. A randomized controlled trial of stapled versus ultrasonic transection in distal pancreatectomy. *Surg Endosc* 2022; **36**: 4033-4041 [PMID: 34518950 DOI: 10.1007/s00464-021-08724-3]

93 **Suzuki Y**, Fujino Y, Tanioka Y, Hori Y, Ueda T, Takeyama Y, Tominaga M, Ku Y, Yamamoto YM, Kuroda Y. Randomized clinical trial of ultrasonic dissector or conventional division in distal pancreatectomy for non-fibrotic pancreas. *Br J Surg* 1999; **86**: 608-611 [PMID: 10361178 DOI: 10.1046/j.1365-2168.1999.01120.x]

94 **Dokmak S**, Ftériche FS, Meniconi RL, Aussilhou B, Duquesne I, Perrone G, Romdhani C, Belghiti J, Lévy P, Soubrane O, Sauvanet A. Pancreatic fistula following laparoscopic distal pancreatectomy is probably unrelated to the stapler size but to the drainage modality and significantly decreased with a small suction drain. *Langenbecks Arch Surg* 2019; **404**: 203-212 [PMID: 30739172 DOI: 10.1007/s00423-019-01756-3]

95 **Aoki T**, Mansour DA, Koizumi T, Matsuda K, Kusano T, Wada Y, Hakozaki T, Tomioka K, Hirai T, Yamazaki T, Watanabe M, Otsuka K, Gahin AEA, Murakami M. Preventing clinically relevant pancreatic fistula with combination of linear stapling plus continuous suture of the stump in laparoscopic distal pancreatectomy. *BMC Surg* 2020; **20**: 223 [PMID: 33023558 DOI: 10.1186/s12893-020-00876-8]

96 **Deng Y**, He S, Cheng Y, Cheng N, Gong J, Gong J, Zeng Z, Zhao L. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. *Cochrane Database Syst Rev* 2020; **3**: CD009621 [PMID: 32157697 DOI: 10.1002/14651858.CD009621.pub4]

97 **Sa Cunha A**, Carrere N, Meunier B, Fabre JM, Sauvanet A, Pessaux P, Ortega-Deballon P, Fingerhut A, Lacaine F; French Fédération de Recherche EN Chirurgie (FRENCH). Stump closure reinforcement with absorbable fibrin collagen sealant sponge (TachoSil) does not prevent pancreatic fistula after distal pancreatectomy: the FIABLE multicenter controlled randomized study. *Am J Surg* 2015; **210**: 739-748 [PMID: 26160763 DOI: 10.1016/j.amjsurg.2015.04.015]

98 **Sista F**, Schietroma M, Santis GD, Mattei A, Cecilia EM, Piccione F, Leardi S, Carlei F, Amicucci G. Systemic inflammation and immune response after laparotomy vs laparoscopy in patients with acute cholecystitis, complicated by peritonitis. *World J Gastrointest Surg* 2013; **5**: 73-82 [PMID: 23717743 DOI: 10.4240/wjgs.v5.i4.73]

99 **Zheng R**, Wang O, Bradley E, Lavu H, Winter JR, Rosato EL, Palazzo F, Yeo CJ, Berger AC. Minimally Invasive Distal Pancreatectomy Is Associated with Decreased Postoperative Neutrophil to Lymphocyte Ratio. *J Pancreat Cancer* 2020; **6**: 32-39 [PMID: 32462109 DOI: 10.1089/pancan.2019.0020]

100 **Yang DJ**, Xiong JJ, Lu HM, Wei Y, Zhang L, Lu S, Hu WM. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. *Sci Rep* 2019; **9**: 1159 [PMID: 30718559 DOI: 10.1038/s41598-018-37617-0]

101 **Shin SH**, Kim SC, Song KB, Hwang DW, Lee JH, Lee D, Lee JW, Jun E, Park KM, Lee YJ. A comparative study of laparoscopic vs. open distal pancreatectomy for left-sided ductal adenocarcinoma: a propensity score-matched analysis. *J Am Coll Surg* 2015; **220**: 177-185 [PMID: 25529901 DOI: 10.1016/j.jamcollsurg.2014.10.014]

102 **Dembinski J**, Cannella R, Sauvanet A, Dokmak S. Laparoscopic spleen-preserving distal pancreatectomy with splenic vessels resection (laparoscopic Warshaw procedure). *J Visc Surg* 2022; **159**: 415-423 [PMID: 35491391 DOI: 10.1016/j.jviscsurg.2022.03.002]

103 **Hang K**, Zhou L, Liu H, Huang Y, Zhang H, Tan C, Xiong J, Li K. Splenic vessels preserving versus Warshaw technique in spleen preserving distal pancreatectomy: A systematic review and meta-analysis. *Int J Surg* 2022; **103**: 106686 [PMID: 35605839 DOI: 10.1016/j.ijsu.2022.106686]

104 **Takagi K**, Umeda Y, Yoshida R, Yagi T, Fujiwara T. The Gastrohepatic Ligament Approach in Robotic Spleen-Preserving Distal Pancreatectomy with Resection of the Splenic Vessels: The Superior Window Approach in the Warshaw Technique. *J Gastrointest Surg* 2022; **26**: 1342-1344 [PMID: 35277800 DOI: 10.1007/s11605-022-05286-0]

105 **Ban D**, Garbarino GM, Ishikawa Y, Honda G, Jang JY, Kang CM, Maekawa A, Murase Y, Nagakawa Y, Nishino H, Ohtsuka T, Yiengpruksawan A, Endo I, Tsuchida A, Nakamura M; Study group of Precision Anatomy for Minimally Invasive Hepato-Biliary-Pancreatic surgery (PAM-HBP surgery). Surgical approaches for minimally invasive distal pancreatectomy: A systematic review. *J Hepatobiliary Pancreat Sci* 2022; **29**: 151-160 [PMID: 33527758 DOI: 10.1002/jhbp.902]

106 **Liang S**, Hameed U, Jayaraman S. Laparoscopic pancreatectomy: indications and outcomes. *World J Gastroenterol* 2014; **20**: 14246-14254 [PMID: 25339811 DOI: 10.3748/wjg.v20.i39.14246]

107 **Bonavina L**. Spleen-preserving laparoscopic distal pancreatectomy: is it worthwhile? *Laparosc Surg* 2019; **3**: 28

108 **Jean-Philippe Adam**, Alexandre Jacquin, Christophe Laurent, Denis Collet, Masson B, Fernández-Cruz L, Sa-Cunha A. Laparoscopic spleen-preserving distal pancreatectomy: splenic vessel preservation compared with the Warshaw technique. *JAMA Surg* 2013; **148**: 246-252 [PMID: 23682365 DOI: 10.1001/jamasurg.2013.768]

109 **Warshaw AL**. Distal pancreatectomy with preservation of the spleen. *J Hepatobiliary Pancreat Sci* 2010; **17**: 808-812 [PMID: 19882099 DOI: 10.1007/s00534-009-0226-z]

110 **Kimura W**, Yano M, Sugawara S, Okazaki S, Sato T, Moriya T, Watanabe T, Fujimoto H, Tezuka K, Takeshita A, Hirai I. Spleen-preserving distal pancreatectomy with conservation of the splenic artery and vein: techniques and its significance. *J Hepatobiliary Pancreat Sci* 2010; **17**: 813-823 [PMID: 20024588 DOI: 10.1007/s00534-009-0250-z]

111 **Butturini G**, Inama M, Malleo G, Manfredi R, Melotti GL, Piccoli M, Perandini S, Pederzoli P, Bassi C. Perioperative and long-term results of laparoscopic spleen-preserving distal pancreatectomy with or without splenic vessels conservation: a retrospective analysis. *J Surg Oncol* 2012; **105**: 387-392 [PMID: 22025322 DOI: 10.1002/jso.22117]

112 **Chen K**, Pan Y, Mou YP, Yan JF, Zhang RC, Zhang MZ, Zhou JY, Wang XF, Maher H, Chen QL. Surgical outcomes of laparoscopic distal pancreatectomy in elderly and octogenarian patients: a single-center, comparative study. *Surg Endosc* 2019; **33**: 2142-2151 [PMID: 30361968 DOI: 10.1007/s00464-018-6489-1]

113 **Hong S**, Song KB, Madkhali AA, Hwang K, Yoo D, Lee JW, Youn WY, Alshammary S, Park Y, Lee W, Kwon J, Lee JH, Hwang DW, Kim SC. Robotic versus laparoscopic distal pancreatectomy for left-sided pancreatic tumors: a single surgeon's experience of 228 consecutive cases. *Surg Endosc* 2020; **34**: 2465-2473 [PMID: 31463719 DOI: 10.1007/s00464-019-07047-8]

114 **Khachfe HH**, Habib JR, Harthi SA, Suhool A, Hallal AH, Jamali FR. Robotic pancreas surgery: an overview of history and update on technique, outcomes, and financials. *J Robot Surg* 2022; **16**: 483-494 [PMID: 34357526 DOI: 10.1007/s11701-021-01289-2]

115 **Rompianesi G**, Montalti R, Ambrosio L, Troisi RI. Robotic versus Laparoscopic Surgery for Spleen-Preserving Distal Pancreatectomies: Systematic Review and Meta-Analysis. *J Pers Med* 2021; **11** [PMID: 34199314 DOI: 10.3390/jpm11060552]

116 **Yang SJ**, Hwang HK, Kang CM, Lee WJ. Revisiting the potential advantage of robotic surgical system in spleen-preserving distal pancreatectomy over conventional laparoscopic approach. *Ann Transl Med* 2020; **8**: 188 [PMID: 32309335 DOI: 10.21037/atm.2020.01.80]

117 **Chen C**, Hu J, Yang H, Zhuo X, Ren Q, Feng Q, Wang M. Is robotic distal pancreatectomy better than laparoscopic distal pancreatectomy after the learning curve? A systematic review and meta-analysis. *Front Oncol* 2022; **12**: 954227 [PMID: 36106111 DOI: 10.3389/fonc.2022.954227]

118 **Bodner J**, Augustin F, Wykypiel H, Fish J, Muehlmann G, Wetscher G, Schmid T. The da Vinci robotic system for general surgical applications: a critical interim appraisal. *Swiss Med Wkly* 2005; **135**: 674-678 [PMID: 16453207 DOI: 10.4414/smw.2005.11022]

119 **Velasquez CA**, Navkar NV, Alsaied A, Balakrishnan S, Abinahed J, Al-Ansari AA, Jong Yoon W. Preliminary design of an actuated imaging probe for generation of additional visual cues in a robotic surgery. *Surg Endosc* 2016; **30**: 2641-2648 [PMID: 26679175 DOI: 10.1007/s00464-015-4270-2]

120 **Kornaropoulos M**, Moris D, Beal EW, Makris MC, Mitrousias A, Petrou A, Felekouras E, Michalinos A, Vailas M, Schizas D, Papalampros A. Total robotic pancreaticoduodenectomy: a systematic review of the literature. *Surg Endosc* 2017; **31**: 4382-4392 [PMID: 28389798 DOI: 10.1007/s00464-017-5523-z]

121 **Zhang J**, Wu WM, You L, Zhao YP. Robotic versus open pancreatectomy: a systematic review and meta-analysis. *Ann Surg Oncol* 2013; **20**: 1774-1780 [PMID: 23504140 DOI: 10.1245/s10434-012-2823-3]

122 **Feng Q**, Jiang C, Feng X, Du Y, Liao W, Jin H, Liao M, Zeng Y, Huang J. Robotic Versus Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. *Front Oncol* 2021; **11**: 752236 [PMID: 34616686 DOI: 10.3389/fonc.2021.752236]

123 **Gavriilidis P**, Roberts KJ, Sutcliffe RP. Comparison of robotic vs laparoscopic vs open distal pancreatectomy. A systematic review and network meta-analysis. *HPB (Oxford)* 2019; **21**: 1268-1276 [PMID: 31080086 DOI: 10.1016/j.hpb.2019.04.010]

124 **van Hilst J**, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, Alseidi A, Ateeb Z, Balzano G, Berrevoet F, Björnsson B, Boggi U, Busch OR, Butturini G, Casadei R, Del Chiaro M, Chikhladze S, Cipriani F, van Dam R, Damoli I, van Dieren S, Dokmak S, Edwin B, van Eijck C, Fabre JM, Falconi M, Farges O, Fernández-Cruz L, Forgione A, Frigerio I, Fuks D, Gavazzi F, Gayet B, Giardino A, Groot Koerkamp B, Hackert T, Hassenpflug M, Kabir I, Keck T, Khatkov I, Kusar M, Lombardo C, Marchegiani G, Marshall R, Menon KV, Montorsi M, Orville M, de Pastena M, Pietrabissa A, Poves I, Primrose J, Pugliese R, Ricci C, Roberts K, Røsok B, Sahakyan MA, Sánchez-Cabús S, Sandström P, Scovel L, Solaini L, Soonawalla Z, Souche FR, Sutcliffe RP, Tiberio GA, Tomazic A, Troisi R, Wellner U, White S, Wittel UA, Zerbi A, Bassi C, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. *Ann Surg* 2019; **269**: 10-17 [PMID: 29099399 DOI: 10.1097/SLA.0000000000002561]

125 **Alfieri S**, Butturini G, Boggi U, Pietrabissa A, Morelli L, Vistoli F, Damoli I, Peri A, Fiorillo C, Pugliese L, Ramera M, De Lio N, Di Franco G, Esposito A, Landoni L, Rosa F, Menghi R, Doglietto GB, Quero G; Italian Robotic pNET Group. Short-term and long-term outcomes after robot-assisted versus laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors (pNETs): a multicenter comparative study. *Langenbecks Arch Surg* 2019; **404**: 459-468 [PMID: 31055639 DOI: 10.1007/s00423-019-01786-x]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Società Italiana di Chirurgia; Associazione Chirurghi Ospedalieri d’Italia; Società Italiana di Chirurgia Oncologica.

**Peer-review started:** January 5, 2023

**First decision:** January 20, 2023

**Article in press:**

**Specialty type:** Surgery

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Erözkan K, Turkey; Murariu MS, Romania **S-Editor:** Chen YL **L-Editor:** A **P-Editor:**

**Table 1** **State of the art of distal pancreatectomy and future directions**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Planned operation**  | **To be considered** | **Present** | **Ongoing research** | **To be matched with** |
| DP | Age, comorbidities | Laparoscopic | Robotic | Laparoscopy |
| DP + splenectomy | Age, comorbidities, cancer, local anatomy | Laparoscopic | Robotic | Laparoscopy |
| RAMPS | Age, comorbidities, cancer | Laparoscopic, open | Robotic | Open surgery |
| DP-CAR | Age, comorbidities, cancer | Open | Laparoscopic, robotic | Open surgery |

DP: Distal pancreatectomy; RAMPS: Radical proximal-distal modular pancreatosplenectomy; DP-CAR: Distal pancreatectomy with celiac axis resection.